^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | PTPN11 inhibitor + ERK inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A combination vertical inhibition approach with inhibitors of SHP2 and ERK provides improved activity in KRAS-mutant pancreatic and colorectal cancer models
Published date:
10/12/2022
Excerpt:
Treatment with the combination more effectively inhibited the growth of KRAS-mutant xenograft tumors in vivo, such as KRASG12C-mutant Mia-PaCa2 xenografts, when compared to either single agent….These data support our hypothesis that the combination of SHP2 and ERK inhibitors enhances inhibition of cell growth over the single agents in KRAS-mutant PDAC and CRC cell lines.
